Page 3 - அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் இதயம் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 27, 2021 Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff. That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall healthcare costs in those nations, investigators led by Justin Parizo, MD (Stanford University, CA), say. “Cost-effectiveness analyses are inherently tied to the society in which they’re evaluated,” senior author Alexander Sandhu, MD (Stanford University), explained to TCTMD. “While the clinical benefits might be quite similar across different contexts and populations, the costs of therapy

United statesUnited kingdomJustin parizoAlexander sandhuDaniel markCenters for diseaseDrug administrationMd stanford universityDuke clinical research instituteAmerican college of cardiology heart associationStanford universityDisease controlAmerican collegeAmerican heart associationDerek chewஒன்றுபட்டது மாநிலங்களில்